Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic (low oxygen) tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen and thereby maximizing the therapeutic effects of radiotherapy.

AllFocal Optics specializes in nanophotonic technology for display enhancement. Its innovative solutions aim to provide natural visual clarity and comfort, addressing physical discomforts such as headaches associated with current AR/VR glasses.

Ultima Forma, based in the UK, is a pioneering manufacturer focused on developing advanced metallic engineering components. The company specializes in creating intricate, lightweight, high-strength parts featuring tailored nanoengineered characteristics across multiple materials. Their innovative process enables them to produce complex 3D structures with locally optimized properties, offering versatile solutions for various industries.

Beta Bugs specializes in insect genetics, developing high-performance Black Soldier Fly breeds for insect farmers. Headquartered at Easter Bush Campus, it collaborates with the Roslin Institute to enhance productivity in the insect protein sector.

Quinas is a leading-edge developer of revolutionary next-generation dual-use semiconductor memory technology designed to drive the proliferation of intelligent devices for Future Compute, Novel AI and Military/Aerospace. ULTRARAM is a revolutionary new type of computer memory that was invented and is under development in the Physics Department at Lancaster University. It combines speed, endurance, retention, and energy efficiency into a single memory concept. These astonishing properties are achieved by harnessing a quantum mechanical effect called resonant tunnelling. Benefits to end user: Ultra-efficient - extending battery life and/or reducing battery weight in the field Non-volatile - data retained in the absence of power, instant reboot for fast response when power is restored. High endurance - high reliability with long lifetime High performance - no compromise in speed despite non-volatility Low carbon – reduces large system power consumption. Sectors: -Future Compute -Novel AI -Data Centres -Automotive -Military/Aerospace

Metalchemy is a nanotechnology company focused on green nanomaterials, bio-nanotechnology, and bioplastics. It develops products derived from green nanomaterials and converts waste into nanomaterials, enabling industries to access eco-friendly nanotechnology to reduce food waste and address the climate crisis, with the goal of a healthier and more sustainable future.

Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.

Intrinsic Semiconductor Technologies develops silicon oxide–based memristive devices with fully air-stable, CMOS-compatible technology. The company specializes in non-volatile and multilevel memory, and its platforms support hardware acceleration for machine learning and neuromorphic computing. Its memristive materials leverage common processing steps to enable integration in standard devices across advanced process nodes, facilitating operation at higher power, frequency, and temperature ranges. In addition to memory functions, the technology underpins low-power, cost-efficient semiconductors, including gallium nitride materials, suitable for diverse applications in data storage, processing, and next-generation computing architectures.

NIQS Technology is a spin-out from the University of Leeds specializing in innovative quantum glucose management solutions aimed at transforming diabetes care. The company has developed a patented, non-invasive glucose monitoring technology that employs a contact-based wearable device made of nano-engineered glass. This device mimics the optical properties of glucose, allowing for continuous, accurate glucose level monitoring without the need for needles or blood sampling. By providing accessible and user-friendly monitoring solutions, NIQS Technology seeks to empower individuals living with diabetes to manage their condition more effectively and improve their overall quality of life, while minimizing the risk of complications associated with traditional glucose management methods.

Silveray develops affordable large-area direct conversion detectors for the X-ray imaging market.

Dyman Advanced Materials specializes in the development of a patented technology aimed at enhancing the manufacturing process of synthetic diamonds. This innovative approach seeks to improve the efficiency of the traditional high-pressure and high-temperature method used in diamond synthesis, resulting in reduced production costs. By providing a more economical production method, Dyman's technology serves both the industrial and gemstone market sectors, facilitating the broader availability of high-quality synthetic diamonds.

Ionoptika is the provider of high-performance ion beam technologies for surface analysis and nanofabrication applications, and are the experts in cluster ion beams for secondary ion mass spectrometry (SIMS).

Anaphite is a Bristol, United Kingdom-based company that develops graphene-based nanomaterials. Established in 2016, it focuses on graphene-enhanced cathodes for high-power, high-energy, low-cost lithium-ion batteries. Its nanomaterials are produced by incorporating graphene into composite materials through an inexpensive, scalable process, enabling a range of applications. Beyond energy storage, the technology is positioned to support air purification and thermal management, offering materials with advanced properties at low cost.

Founded in 2015 and based in Cambridge, UK, Camallergy is a biopharmaceutical company focused on developing innovative treatments for food allergies. Its lead product is an oral immunotherapy designed to provide significant protection against peanut allergy within just three months.

Iceni Labs is an innovation commercialisation enterprise, with integrated research, development, test and manufacturing capability. Inter-disciplinary by nature, we combine commercial expertise with academic excellence, across the Defence and Security, Energy, Health and Consumer sectors. Our professional networks bridge artificial intelligence, automated creativity, electronics, energy, materials, nanotechnology and software. We invent and innovate in-house, foster high-potential technologies, and aggregate capabilities globally, to produce innovative, disruptive products that deliver more than the sum of their parts. By providing technical, executive, commercial and capital support, our Innovation-Exploitation Programme enhances value proposition and reduces risk exposure, while developing creativity, flexibility and robustness. Our goal is for our ‘wrap around’ idea to patent to product approach to become recognised globally as a catalyst for successful innovation. We are bridging the challenging gap between ‘thinking’ and ‘doing’.

Glaia develops nanotechnology-based solutions for sustainable agriculture, aiming to improve crop yields and reduce pressure on natural resources.

Iceni Labs is an innovation commercialisation enterprise, with integrated research, development, test and manufacturing capability. Inter-disciplinary by nature, we combine commercial expertise with academic excellence, across the Defence and Security, Energy, Health and Consumer sectors. Our professional networks bridge artificial intelligence, automated creativity, electronics, energy, materials, nanotechnology and software. We invent and innovate in-house, foster high-potential technologies, and aggregate capabilities globally, to produce innovative, disruptive products that deliver more than the sum of their parts. By providing technical, executive, commercial and capital support, our Innovation-Exploitation Programme enhances value proposition and reduces risk exposure, while developing creativity, flexibility and robustness. Our goal is for our ‘wrap around’ idea to patent to product approach to become recognised globally as a catalyst for successful innovation. We are bridging the challenging gap between ‘thinking’ and ‘doing’.

Dyman Advanced Materials specializes in the development of a patented technology aimed at enhancing the manufacturing process of synthetic diamonds. This innovative approach seeks to improve the efficiency of the traditional high-pressure and high-temperature method used in diamond synthesis, resulting in reduced production costs. By providing a more economical production method, Dyman's technology serves both the industrial and gemstone market sectors, facilitating the broader availability of high-quality synthetic diamonds.

Anaphite is a Bristol, United Kingdom-based company that develops graphene-based nanomaterials. Established in 2016, it focuses on graphene-enhanced cathodes for high-power, high-energy, low-cost lithium-ion batteries. Its nanomaterials are produced by incorporating graphene into composite materials through an inexpensive, scalable process, enabling a range of applications. Beyond energy storage, the technology is positioned to support air purification and thermal management, offering materials with advanced properties at low cost.

Iceni Labs is an innovation commercialisation enterprise, with integrated research, development, test and manufacturing capability. Inter-disciplinary by nature, we combine commercial expertise with academic excellence, across the Defence and Security, Energy, Health and Consumer sectors. Our professional networks bridge artificial intelligence, automated creativity, electronics, energy, materials, nanotechnology and software. We invent and innovate in-house, foster high-potential technologies, and aggregate capabilities globally, to produce innovative, disruptive products that deliver more than the sum of their parts. By providing technical, executive, commercial and capital support, our Innovation-Exploitation Programme enhances value proposition and reduces risk exposure, while developing creativity, flexibility and robustness. Our goal is for our ‘wrap around’ idea to patent to product approach to become recognised globally as a catalyst for successful innovation. We are bridging the challenging gap between ‘thinking’ and ‘doing’.

Nanna Therapeutics Limited, established in 2012 and headquartered in Cambridge, UK, is a biotechnology company focused on developing drugs for age-related diseases such as mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases, and cancer. As of April 2020, the company operates as a subsidiary of Astellas Pharma Europe Ltd. Nanna Therapeutics employs a unique approach by targeting fundamental cellular processes to create innovative treatments for these conditions, with a particular emphasis on mitochondria, the energy source in every cell. The company's proprietary drug discovery platform, TIME (Totally Integrated Medicines Engine), combines advanced technologies like microfluidics and artificial intelligence to accelerate drug development and disrupt traditional methods of creating new medicines.

Anaphite is a Bristol, United Kingdom-based company that develops graphene-based nanomaterials. Established in 2016, it focuses on graphene-enhanced cathodes for high-power, high-energy, low-cost lithium-ion batteries. Its nanomaterials are produced by incorporating graphene into composite materials through an inexpensive, scalable process, enabling a range of applications. Beyond energy storage, the technology is positioned to support air purification and thermal management, offering materials with advanced properties at low cost.

Beta Bugs specializes in insect genetics, developing high-performance Black Soldier Fly breeds for insect farmers. Headquartered at Easter Bush Campus, it collaborates with the Roslin Institute to enhance productivity in the insect protein sector.

Irresistible Materials Ltd is a materials technology company based in Swansea, United Kingdom, specializing in the development and commercialization of fullerene-based photoresist technology. Founded in 2010 as a spin-out from the University of Birmingham, the company collaborates with Nano-C Inc in the United States to create advanced materials for next-generation lithography applications. Irresistible Materials focuses on providing innovative solutions, including EUV resists, spin-on-carbon, and e-beam resists, aimed at meeting the demands of the semiconductor industry for increasingly smaller microchip feature sizes. The company has established a robust patent portfolio that encompasses various resist and hard-mask materials and maintains strong partnerships with the University of Birmingham and a network of global collaborators to further advance its materials offerings.

Xerion Healthcare Limited is a biotechnology company based in Thame, United Kingdom, specializing in the development and commercialization of nanoparticle treatments for cancer. Founded in 2015, the company focuses on enhancing the efficacy of conventional radiotherapy by utilizing nanoparticles made from titanium dioxide, a non-toxic semiconductor material. These nanoparticles are injected into tumors prior to standard radiotherapy, where they amplify the generation of free radicals produced by X-rays, thereby improving treatment outcomes. Xerion Healthcare is particularly concentrated on developing its innovative technology for head, neck, and pancreatic cancers, aiming to provide more effective therapies while minimizing side effects for patients.

LIFNano Therapeutics is a clinical-stage biotechnology company founded in 2013 as a spin-out from the University of Cambridge. The company specializes in the targeted delivery of Leukaemia Inhibitory Factor (LIF), utilizing advanced nanotechnology to develop therapeutics aimed at treating multiple sclerosis and other neurodegenerative diseases. By focusing on the precise delivery of biologics, LIFNano aims to repair damaged tissues, particularly neurons in the brain and spinal cord. This approach provides patients with a potential natural treatment option for multiple sclerosis and inflammatory diseases affecting the brain and immune system.

Tecrea develops nanotechnology-powered tools for cell and tissue delivery that translate from laboratory research to clinical application. The company focuses on basic research that yields transformative biomedicine technologies and aims to improve the delivery of reagents and drugs into cells, addressing delivery as a central challenge in biology and medicine. Its platform provides transfection reagents and delivery tools designed to enable precise, rapid, and scalable introduction of genetic and molecular payloads with minimal cytotoxicity and high reproducibility across workflows. By enhancing delivery capabilities, Tecrea supports researchers and therapeutic developers in achieving more efficient drug delivery and clearer experimental outcomes, advancing molecular medicine toward clinical use.